<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03673657</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO-1041</org_study_id>
    <nct_id>NCT03673657</nct_id>
  </id_info>
  <brief_title>Study of Oral Nutritional Supplements During Concurrent Chemoradiotherapy for Local Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>A Prospective, Randomized, Phase II Study of Oral Nutritional Supplements During Concurrent Chemoradiotherapy for Local Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II randomized study is to determine the efficacy of oral nutritional
      supplements(ONS) during concurrent chemoradiotherapy for local advanced non-small cell lung
      cancer, and discuss when to deliver ONS and which indicator should be the goal of ONS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II randomized study is to determine the efficacy of oral nutritional
      supplements(ONS) during concurrent chemoradiotherapy for local advanced non-small cell lung
      cancer, and discuss when to deliver ONS and which indicator should be the goal of ONS.

      Patients were randomly assigned to arm A, B, C, D. In arm A, ONS is given from start of CCRT,
      based on the daily total nutritional intake of 30-35kcal/kg. Patients in arm B are given ONS
      when they have grade 2 radiation esophagitis, based on the daily total nutritional intake of
      30-35kcal/kg. For arm C, ONS is given from start of CCRT, with the goal to keep prealbumin
      normal. Patients in arm D are given ONS when they have grade 2 radiation esophagitis, with
      the goal to keep prealbumin normal. All patients received definitive thoracic radiotherapy
      with total radiation doses of 60-70 Gy, concurrent with weekly docetaxel(25mg/㎡) and
      nedaplatin(25mg/㎡).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>up to 2 months after radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin change</measure>
    <time_frame>up to 2 months after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>albumin change</measure>
    <time_frame>up to 2 months after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scored Patient-Generated Subjective Global Assessment</measure>
    <time_frame>up to 2 months after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of grade 3-4 radiation esophagitis</measure>
    <time_frame>up to 1 year after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of grade 3-4 radiation pneumonitis</measure>
    <time_frame>up to 1 year after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Local Advanced Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONS from the start of radiotherapy; Energy goal-based ONS: daily total nutritional intake of 30-35kcal/kg.
Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONS from the time of grade 2 radiation esophagitis; Energy goal-based ONS: daily total nutritional intake of 30-35kcal/kg.
Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONS from the start of radiotherapy; Prealbumin goal-based ONS. Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONS from the time of grade 2 radiation esophagitis; Prealbumin goal-based ONS. Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ONS from the start of radiotherapy</intervention_name>
    <description>ONS from the start of radiotherapy</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ONS from the time of grade 2 radiation esophagitis</intervention_name>
    <description>ONS from the time of grade 2 radiation esophagitis</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Energy goal-based ONS</intervention_name>
    <description>Energy goal-based ONS</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prealbumin goal-based ONS</intervention_name>
    <description>Prealbumin goal-based ONS</description>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thoracic radiotherapy</intervention_name>
    <description>Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Weekly DP chemotherapy concurrent with thoracic radiotherapy</intervention_name>
    <description>Weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with thoracic radiotherapy</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed non-small cell lung cancer.

          -  Recieved definitive concurrent chemoradiotherapy.

          -  Pretreatment PG-SGA score A to B.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  Estimated life expectancy of at least 6 months.

          -  Without contraindication for chemoradiotherapy.

        Exclusion Criteria:

          -  Severe impairment of intestinal function, or intolerance of enteral nutrition.

          -  Severe vomiting, gastrointestinal bleeding, or intestinal obstruction.

          -  Severe malnutrition, or intolerance of chemoradiotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Liu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Qiu, Attending</last_name>
    <phone>+86-020-87343031</phone>
    <email>qiubo@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Liu, Professor</last_name>
    <phone>+86-020-87343031</phone>
    <email>liuhui@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Qiu, Attending</last_name>
      <phone>+86-020-87343031</phone>
      <email>qiubo@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Hui Liu, Professor</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bovio G, Montagna G, Bariani C, Baiardi P. Upper gastrointestinal symptoms in patients with advanced cancer: relationship to nutritional and performance status. Support Care Cancer. 2009 Oct;17(10):1317-24. doi: 10.1007/s00520-009-0590-x. Epub 2009 Feb 8.</citation>
    <PMID>19199106</PMID>
  </reference>
  <reference>
    <citation>Kiss N, Isenring E, Gough K, Krishnasamy M. The prevalence of weight loss during (chemo)radiotherapy treatment for lung cancer and associated patient- and treatment-related factors. Clin Nutr. 2014 Dec;33(6):1074-80. doi: 10.1016/j.clnu.2013.11.013. Epub 2013 Nov 25.</citation>
    <PMID>24325888</PMID>
  </reference>
  <reference>
    <citation>Unsal D, Mentes B, Akmansu M, Uner A, Oguz M, Pak Y. Evaluation of nutritional status in cancer patients receiving radiotherapy: a prospective study. Am J Clin Oncol. 2006 Apr;29(2):183-8.</citation>
    <PMID>16601440</PMID>
  </reference>
  <reference>
    <citation>Luo J, Chen YJ, Narsavage GL, Ducatman A. Predictors of survival in patients with non-small cell lung cancer. Oncol Nurs Forum. 2012 Nov;39(6):609-16. doi: 10.1188/12.ONF.609-616.</citation>
    <PMID>23107855</PMID>
  </reference>
  <reference>
    <citation>Sánchez-Lara K, Turcott JG, Juárez E, Guevara P, Núñez-Valencia C, Oñate-Ocaña LF, Flores D, Arrieta O. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study. Nutr Cancer. 2012;64(4):526-34. doi: 10.1080/01635581.2012.668744. Epub 2012 Apr 10.</citation>
    <PMID>22489794</PMID>
  </reference>
  <reference>
    <citation>Ma L, Ye W, Li Q, Wang B, Luo G, Chen Z, Guo S, Qiu B, Liu H. Subjective Global Assessment (SGA) Score Could Be a Predictive Factor for Radiation Pneumonitis in Lung Cancer Patients With Normal Pulmonary Function Treated by Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy. Clin Lung Cancer. 2018 Mar;19(2):e211-e217. doi: 10.1016/j.cllc.2017.09.001. Epub 2017 Sep 19.</citation>
    <PMID>29017827</PMID>
  </reference>
  <reference>
    <citation>Isenring EA, Capra S, Bauer JD. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. Br J Cancer. 2004 Aug 2;91(3):447-52.</citation>
    <PMID>15226773</PMID>
  </reference>
  <reference>
    <citation>Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck. 2005 Aug;27(8):659-68.</citation>
    <PMID>15920748</PMID>
  </reference>
  <reference>
    <citation>Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol. 2005 Mar 1;23(7):1431-8. Epub 2005 Jan 31.</citation>
    <PMID>15684319</PMID>
  </reference>
  <reference>
    <citation>Kiss NK, Krishnasamy M, Isenring EA. The effect of nutrition intervention in lung cancer patients undergoing chemotherapy and/or radiotherapy: a systematic review. Nutr Cancer. 2014;66(1):47-56. doi: 10.1080/01635581.2014.847966. Epub 2013 Dec 9. Review.</citation>
    <PMID>24320097</PMID>
  </reference>
  <reference>
    <citation>Sanders KJ, Hendriks LE, Troost EG, Bootsma GP, Houben RM, Schols AM, Dingemans AM. Early Weight Loss during Chemoradiotherapy Has a Detrimental Impact on Outcome in NSCLC. J Thorac Oncol. 2016 Jun;11(6):873-9. doi: 10.1016/j.jtho.2016.02.013. Epub 2016 Mar 3.</citation>
    <PMID>26940529</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>September 14, 2018</last_update_submitted>
  <last_update_submitted_qc>September 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hui Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Local Advanced Non-small Cell Lung Cancer</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Oral Nutritional Supplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

